GEG vs BOLD Comparison

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. The Group conducts its operations through two business segments: Alternative Credit and Real Estate. Key revenue comes from the Real Estate segment, which includes a full-service, end-to-end real estate platform combining investment expertise and turnkey execution capabilities for the IOS sector. The Alternative Credit segment focuses on income generation and capital preservation by investing in debt and income-generating securities, direct lending, CLOs, and specialty finance businesses, including factoring, asset-based lending, and healthcare.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.